Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 88, Issue 1, 2010, Pages 71-75

  Xu, Dan yan ^a   Zhao, Shui Ping ^a   Huang, Qiu xia ^b   Du, Wei ^b   Liu, Yu hua ^b   Liu, Ling ^a   Xie, Xiao mei ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b DONGGUAN PEOPLE'S HOSPITAL   (China)

Author keywords

Blood glucose (BG); Glimepiride; Plasma lipoprotein; Plasminogen activator inhibitor type I (PAI 1); Tissue plasminogen activator (t PA); Type 2 diabetes mellitus (T2DM)

Indexed keywords

CHOLESTEROL; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIET RESTRICTION; DRUG ACTIVITY; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISK FACTORS; SULFONYLUREA COMPOUNDS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 77649235702     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2009.12.010     Document Type: Article

References (24)

1. Dedoussis G.V., Kaliora A.C., and Panagiotakos D.B. Genes, diet and type 2 diabetes mellitus: a review. Rev. Diabet. Stud. 4 Spring (1) (2007) 13-24
2. Reusch J.E., and Draznin B.B. Atherosclerosis in diabetes and insulin resistance. Diabetes Obes. Metab. 9 July (4) (2007) 455-463
3. Meigs J.B., Nathan D.M., D'Agostino R.B., and Wilson P.W. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham offspring study. Diabetes Care 25 (2002) 1845-1850
4. Barr E.L., Zimmet P.Z., Welborn T.A., Jolley D., Magliano D.J., Dunstan D.W., et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance. The Australian diabetes, obesity, and lifestyle study (AusDiab). Circulation June (2007)
5. Franco O.H., Steyerberg E.W., Hu F.B., Mackenbach J., and Nusselder W. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch. Intern. Med. 167 June (11) (2007) 1145-1151
6. Jeppesen J., Hansen T.W., Rasmussen S., Ibsen H., Torp-Pedersen C., and Madsbad S. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study. J. Am. Coll. Cardiol. 49 May (21) (2007) 2112-2119
7. Godi R., and Samaha F.F. Dyslipidemia in type 2 diabetes mellitus. Curr. Diab. Rep. 7 June (3) (2007) 228-234
8. Howard B.V. Lipoprotein metabolism in diabetes mellitus. J. Lipid Res. 28 (1987) 613-628
9. PyOrft U.K., Laakso M., and Uusltupa M. Diabetes and atherosclerosis: an epktemtologic view. Diabetes/Metab. Rev. 2 (1987) 464-524
10. Sharma S.C. Platelet adhesiveness, plasma fibrinogen and fibrinolytic activity in juvenile onset and maturity onset diabetes mellitus. J. Pathol. 4 (1981) 501-503
11. Festa A., D'Agostino Jr. R., Tracy R.P., and Haffner S.M. Insulin Resistance Atherosclerosis Study. Elevated levels of acute phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 51 (2002) 1131-1137
12. Rosak C. The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents. J. Diabetes Complicat. 16 (2002) 123-132
13. Overkamp D., Volk A., Maerker E., Heide P.E., Wahl H.G., Rett K., et al. Acute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes. Diabetes Care 25 Nov (11) (2002) 2065-2073
14. Waugh N., Scotland G., McNamee P., Gillett M., Brennan A., Goyder E., et al. Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess. 11 May (17) (2007) 1-144
15. Korytkowski M., Thomas A., Reid L., Tedesco M.B., Gooding W.E., and Gerich J. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes. Diabetes Care 25 (2002) 1607-1611
16. Kabadi M.U., and Kabadi U.M. Effects of glimepiride on insulin secretion and sensitivity in patients with recently diagnosed type 2 diabetes mellitus[J]. Clin. Ther. 26 1 (2004) 63-69
17. Tsunekawa T., Hayashi T., Suzuki Y., Matsui-Hirai H., Kano H., Fukatsu A., et al. Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects[J]. Diabetes Care 26 2 (2003) 285-289
18. Gottschalk M., Danne T., Vlajnic A., and Cara J.F. Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study. Diabetes Care 30 April (4) (2007) 790-794
19. Jovanović D., Stojsić D., Zlatković M., Jović-Stosić J., and Jovanović M. Bioequivalence assessment of the two brands of glimepiride tablets. Vojnosanit. Pregl. 63 December (12) (2006) 1015-1020
20. Müller G. The molecular mechanism of the insulin-mimetic/sensitizing activity of the antidiabetic sulfonylurea drug amaryl. Mol. Med. 6 (2000) 907-933
21. Umpierrez G., Issa M., and Vlajnic A. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Curr. Med. Res. Opin. 22 April (4) (2006) 751-759
22. Draeger K.E., Wernicke-Panten K., Lomp H.J., et al. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (amaryl): a double-blind comparison with glibenclamide. Horm. Metab. Res. 28 (1996) 419-425
23. Suenson E., and Petersen L.C. Fibrin and plasminogen structures essential to stimulation of plasmin formation by tissue-type plasminogen activator. Biochim. Biophys. Acta 870 (1986) 510-519
24. Aso Y. Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. Front Biosci. May (12) (2007) 2957-2966